Highbridge Capital Management’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,413,487
| Closed | -$3.31M | – | 465 |
|
|
2022
Q4 | $3.31M | Hold |
2,413,487
| – | – | 0.09% | 194 |
|
|
2022
Q3 | $2.51M | Buy |
+2,413,487
| New | +$2.51M | 0.04% | 305 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 713 |
|
|
2020
Q4 | – | Sell |
-2,414,487
| Closed | -$9.42M | – | 117 |
|
|
2020
Q3 | $9.42M | Hold |
2,414,487
| – | – | 0.51% | 48 |
|
|
2020
Q2 | $9.15M | Sell |
2,414,487
-2,414,487
| -50% | -$9.15M | 0.78% | 31 |
|
|
2020
Q1 | $11.3M | Buy |
+4,828,974
| New | +$11.3M | 1.21% | 31 |
|
|
2018
Q1 | – | Sell |
-47,255
| Closed | -$313K | – | 1024 |
|
|
2017
Q4 | $313K | Sell |
47,255
-410,812
| -90% | -$2.72M | 0.01% | 593 |
|
|
2017
Q3 | $2.66M | Buy |
+458,067
| New | +$2.66M | 0.04% | 321 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 1111 |
|
|
2017
Q1 | – | Sell |
-477,980
| Closed | -$2.13M | – | 1291 |
|
|
2016
Q4 | $2.13M | Buy |
+477,980
| New | +$2.13M | 0.04% | 335 |
|
|
2014
Q1 | – | Sell |
-2,296
| Closed | -$89K | – | 854 |
|
|
2013
Q4 | $89K | Buy |
+2,296
| New | +$89K | ﹤0.01% | 655 |
|